Evidence map›Paper›PMID 41483382›Full record

ArticleDiscover oncology2026

A multi-scale feature fusion of deep learning network for classifying acute leukemia genetic subtypes from blood smear images.

Wuchen Yang, Li Ma, Jigang Xiao, Shuiqing Liu, Zhiwen Luo, Yi Wang, Xingqin Huang, Jingya Liu, Cong Han, Tinglu Tao and 9 more

Abstract read
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Wuchen Yang *Medical Center of Hematology, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
Li Ma *School of Computer Science, Chongqing University, Chongqing, 400044, China.
Jigang Xiao *Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300070, China.
Shuiqing LiuMedical Center of Hematology, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
Zhiwen LuoSchool of Computer Science, Chongqing University, Chongqing, 400044, China.
Yi WangSchool of Computer Science, Chongqing University, Chongqing, 400044, China.
Xingqin HuangDepartment of Hematology, Southwest Hospital of Army Medical University, Chongqing, 400037, China.
Jingya LiuMedical Center of Hematology, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
Cong HanInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300070, China.
Tinglu TaoMedical Center of Hematology, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
Xing QiangMedical Center of Hematology, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
Hongyang ZhangMedical Center of Hematology, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
Yang GouMedical Center of Hematology, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
Yimei FengMedical Center of Hematology, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
Cheng ZhangMedical Center of Hematology, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
Ting HuangShanghai Institute of Hematology, Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. htshcn@126.com.
Xiangui PengMedical Center of Hematology, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China. pxg1964@163.com.
Jing WenSchool of Computer Science, Chongqing University, Chongqing, 400044, China. wj@cqu.edu.cn.
Xi ZhangMedical Center of Hematology, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China. zhangxxi@sina.com.

Funding

Chongqing Major Project for Joint Medical Research by the Science and Health Commission 2024DBXM004Chongqing Major Special Project for Technological Innovation and Application Development CSTB2023TIAD-STX0008
6 · The paper itself

Abstract

Acute leukemia (AL) is a common type of hematological malignancy. Accurate classification of its genetic subtypes is crucial for achieving precise clinical diagnosis and treatment. However, some genetic subtypes lack distinct morphological features and can easily be confused with other AL types. Additionally, genetic subtypes often relies on expensive genetic testing equipment. These factors limit the ability to achieve precise diagnosis of AL in clinical settings. To tackle this clinical challenge, we developed the EMAResDrop model by enhancing pre-trained ResNet50 with DropBlock and Efficient Multi-Scale Attention (EMA) techniques to improve the classification accuracy of genetic subtypes of AL. Our model was evaluated on two AL datasets comprising blood smear images from 469 cases of acute lymphoblastic leukemia (ALL) and 269 cases of acute myeloid leukemia (AML) patients. In the test set for ALL, the EMAResDrop model effectively distinguished between BCR::ABL1, TCF3::PBX1, KMT2A rearrangement, ETV6::RUNX1, and ALL-Others, achieving accuracies of 0.967 ± 0.005, 0.954 ± 0.006, 0.946 ± 0.005, 0.981 ± 0.006, and 0.929 ± 0.002, respectively. Additionally, the classification accuracies for different AML subtypes were 0.992 ± 0.013 for PML::RARA, 0.929 ± 0.004 for RUNX1::RUNX1T1, and 0.926 ± 0.005 for CBFB::MYH11. When compared with four benchmark models (VGG16, InceptionV3, DenseNet121, and ResNet50), EMAResDrop exhibited superior performance, achieving classification accuracies of 0.954 ± 0.015 and 0.949 ± 0.003 for the ALL and AML datasets, respectively. The external test results further confirmed the strong generalization ability of the model. Overall, this study enhanced the genotyping diagnosis of AL and has the potential to improve early diagnosis and treatment, potentially supporting more effective clinical management.

Indexed as

Acute leukemiaAcute lymphoblastic leukemiaAcute myeloid leukemiaDeep learningDropBlockEfficient multi-scale attentionGenetic subtypesResNet50

Identifiers

PMID41483382
PMCPMC12864620

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.